CD274 and neoplasm: Moreover, augmenting miR-4429 levels led to a considerable reduction in CD274 expression and subsequent restraint of the PI3K/AKT signalling pathway, signifying the tumour-suppressive potential of miR-4429 in ccRCC through its targeting of CD274 and control over the PI3K/AKT pathway.